Alzheimer's Disease: Another Target for Heparin Therapy

Alzheimer's Disease: Another Target for Heparin Therapy

Alzheimer's disease (AD) is the leading cause of dementia and cognitive decline in the elderly. Brain tissue changes indicate that the two main proteins involved in AD are amyloid-β(A-β), which is associated with the formation of senile amyloid plaques, and tau, which is associated with the for...

Full description

Bibliographic Details
Main Authors:	Luigi Bergamaschini, Emanuela Rossi, Carlo Vergani, Maria Grazia De Simoni
Format:	Article
Language:	English
Published:	Hindawi Limited 2009-01-01
Series:	The Scientific World Journal
Online Access:	http://dx.doi.org/10.1100/tsw.2009.100

Similar Items

C1-inhibitor protects against brain ischemia–reperfusion injury via inhibition of cell recruitment and inflammation
by: Claudio Storini, et al.
Published: (2005-06-01)

Multi-target-directed ligands: application to the Alzheimer's disease
by: Simoni, Elena <1979>
Published: (2010)

An investigation into the short-term effects of music therapy for patients with probable Alzheimer’s disease or another form of dementia.
by: Clute, O.
Published: (2017-07-01)

Identical drug packaging: Heparin and midazolam-yet another instance of similar drug packaging
by: Misra Satyajeet, et al.
Published: (2009-01-01)

Molecular drug targets and therapies for Alzheimer’s disease
by: Singh Dev, et al.
Published: (2014-09-01)

Cutaneous reactions to heparin therapy: when are they caused by heparin allergy?
by: Giuliana Zisa, et al.
Published: (2013-03-01)

Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer’s and Pick’s diseases
by: Wenjuan Zhang, et al.
Published: (2019-02-01)

Adverse effects of antiretroviral therapy or another disease?
by: Mariana Stanescu, et al.
Published: (2020-09-01)

Heparin and Heparin-Derivatives in Post-Subarachnoid Hemorrhage Brain Injury: A Multimodal Therapy for a Multimodal Disease
by: Erik G. Hayman, et al.
Published: (2017-05-01)

Targeting HDACs: A Promising Therapy for Alzheimer's Disease
by: Ke Xu, et al.
Published: (2011-01-01)

Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update
by: Giovanna Cenini, et al.
Published: (2019-08-01)

Lingo-1: a novel target in therapy for Alzheimer′s disease?
by: Francesca Fernandez-Enright, et al.
Published: (2016-01-01)

The molecular mechanisms of Alzheimer's disease and the promise of novel targeted therapies
by: Lee, Helen Hyewon
Published: (2021)

Heparin and heparin-like molecules inhibit the Alzheimer's β-secretase (BACE1) : considerations for biological assay and future therapeutic development
by: Hadfield, Lynsay Claire
Published: (2018)

Molecular neuropathology of Alzheimer's disease
by: Spillantini, Maria Grazia
Published: (1993)

Neisseria Heparin Binding Antigen is targeted by the human alternative pathway C3-convertase.
by: Martina Di Fede, et al.
Published: (2018-01-01)

Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease
by: Niklas Reich, et al.
Published: (2020-12-01)

Variability in heparin sensitivity of appt reagents in heparinized plasma in vitro and patients receiving heparin
by: Fernanda Daniela Serralvo, et al.
Published: (2015-03-01)

Targeting the Synapse in Alzheimer’s Disease
by: Johanna Jackson, et al.
Published: (2019-07-01)

The role of heparin in inflammatory bowel disease
by: Shetty, Ajeya Krishna
Published: (2011)

A Novel Targeted and High‐Efficiency Nanosystem for Combinational Therapy for Alzheimer's Disease
by: Han Yang, et al.
Published: (2020-10-01)

A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer's disease
by: Dongju Zhao, et al.
Published: (2021-11-01)

The contact activation system and vascular factors as alternative targets for Alzheimer's disease therapy
by: Pradeep K. Singh, et al.
Published: (2021-05-01)

Mitochondrial Dysfunction: Different Routes to Alzheimer’s Disease Therapy
by: Pasquale Picone, et al.
Published: (2014-01-01)

Heparin‐induced thrombocytopenia in end‐stage renal disease: Reliability of the PF4‐heparin ELISA
by: Julie Kelly, et al.
Published: (2021-07-01)

Music Therapy in Mexico: Another Approach
by: Eugenia Hernandez-Ruiz
Published: (2005-07-01)

Disease Modifying Therapies for Alzheimer's Disease Targeting Aβ Oligomers: Implications for Therapeutic Mechanisms
by: Etsuro Matsubara, et al.
Published: (2013-01-01)

Life-threatening hemorrhage following subcutaneous heparin therapy
by: Jana Hudcova, et al.
Published: (2008-12-01)

Peripheral Inflammatory Response in Alzheimer's Disease and Multiinfarct Dementia
by: A. De Luigi, et al.
Published: (2002-11-01)

Targeting eosinophils: another strategy for asthma treatment
by: Hye Mi Jee
Published: (2021-05-01)

Antioxidant Therapies for Alzheimer's Disease
by: Ye Feng, et al.
Published: (2012-01-01)

Targeting of Mycobacterium tuberculosis heparin-binding hemagglutinin to mitochondria in macrophages.
by: Hosung Sohn, et al.
Published: (2011-12-01)

Melatonin Therapy in Patients with Alzheimer’s Disease
by: Daniel P. Cardinali, et al.
Published: (2014-04-01)

Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy
by: Asha Hiremathad, et al.
Published: (2017-01-01)

Triazolopyridopyrimidine: A New Scaffold for Dual-Target Small Molecules for Alzheimer’s Disease Therapy
by: Lazhar Zribi, et al.
Published: (2020-07-01)

Intranasal administration of dauricine loaded on graphene oxide: multi-target therapy for Alzheimer's disease
by: Kaixuan Wang, et al.
Published: (2021-01-01)

Targeting Aggrephagy for the Treatment of Alzheimer’s Disease
by: Sandeep Malampati, et al.
Published: (2020-01-01)

Modeling and Targeting Alzheimer’s Disease With Organoids
by: Angelos Papaspyropoulos, et al.
Published: (2020-03-01)

New Therapeutic Targets in Alzheimer's Disease
by: Horia Coman, et al.
Published: (2017-03-01)

The biomarkers and targeting treatment for Alzheimer's disease
by: Zheng WANG, et al.
Published: (2010-04-01)